• Miao Zhang, Yue Yuan, Ying Gao, Ruozhu Lu, and Yue Deng.
• Doctor of Medicine, School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
• Medicine (Baltimore). 2022 Apr 22; 101 (16): e29153e29153.

BackgroundIn-stent restenosis (ISR) caused by vascular remodeling after percutaneous coronary intervention limits the long-term efficacy of this method. Salvianolate injection is now widely used in the clinical treatment of ISR. However, there is no systematic review or meta-analysis to evaluate the effects of Salvianolate injection on ISR.MethodsWe will search articles in 8 electronic databases, including the Cochrane Central Register of Controlled Trials, PubMed, Embase, the Web of Science, China National Knowledge Infrastructure, the Chinese Biomedical Literature Database, Wanfang Database, and the Chinese Scientific Journal Database for randomized controlled trials of ISR treated by Salvianolate injection from their inception to February 27, 2022. The primary outcome measure will be the restenosis rate. The data meeting the inclusion criteria were analyzed by RevMan V.5.4 software. Two authors evaluated the study using the Cochrane collaborative risk bias tool. We will use a scoring method to assess the overall evidence supporting the main results.ResultsThis study will analyze the clinical effectiveness of Salvianolate injection in the treatment of ISR.ConclusionThe findings of this systematic review will provide evidence to evaluate the effectiveness of Salvianolate injection for the treatment of ISR.Inplasy Registration NumberINPLASY202220117.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

10 keywords...

hide…